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Background: Increasingly, multi-criteria decision analysis has gained importance as a
method by which to assess the value of orphan drugs. However, very little attention
has been given to the weight (relative preferences) of the individual criteria used in
a framework.
Aims: This study sought to gain an understanding of the preferential weights that should
be allocated in a multi-criteria decision analysis framework for orphan drugs, from a
multi-stakeholder perspective.
Method: Using key MCDA criteria for orphan drugs reported in the literature, we
developed an interactive web-based survey tool to capture preferences for different
criteria from a general stakeholder sample who were requested to assign weights from
a reimbursement perspective. Each criterion could be assigned a weight on a sliding
scale from 0 to 100% as long as the sum of all the criteria was 100%. We subsequently
used the interactive tool with an expert focus group, followed up with a group discussion
regarding each criterion and their perspectives on the weight that each criterion should
be allocated when assessing an orphan drug. The expert focus group participants were
then able to adjust their weights, if the group discussion had changed their perspectives.
Results: The interactive tool was completed by 120 general stakeholder sample from
a wide range of countries and professional backgrounds and an expert focus group of
ten members. The results showed the differences in perspectives on the importance of
criteria. Both groups considered Treatment efficacy to be the most important criterion.
The general stakeholder sample weighted Treatment safety at 12.03% compared to
the expert focus group’s average of 20%. The results also demonstrated the value of
the group discussion, which provided additional insights into the perspectives on the
importance of criteria in assessing orphan drugs.
Conclusion: This study aimed to contribute to the important aspect of preferences
for different criteria in MCDA. This study sheds light on the important aspect of the
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preferences of the different criteria. All respondents agreed on the relative importance
of Treatment efficacy and Treatment safety, criteria that are captured in conventional
cost-effectiveness studies, but they also expressed the view that in addition to those,
several disease-related and drug-related criteria should be included inMCDA frameworks
for assessing orphan drugs.
Keywords: multi-criteria decision analysis, interactive tool, focus group, weights, preferences
BACKGROUND
Decision-making in healthcare is usually a process whereby
different alternatives are identified and compared to find the
best solution based on multiple factors that address the decision-
makers’ and the organization’s expectations (1). With the
launching of new and in some cases, innovative treatments such
as gene therapy for rare diseases, it’s likely that the increasing
demands for the reimbursement of such treatments will raise
added concerns on the long-term affordability, especially of
expensive treatments (2, 3). In order to mitigate the uncertainty
of the health benefits of treatments that have been trialed for
relatively short periods of time, healthcare systems might have to
adopt novel ways of reimbursement decision-making, in addition
to cost-effectiveness studies, which is the most commonly used
way of assessing the value-add of a new treatment (4, 5). Several
decision-making approaches have been developed in healthcare,
such as the three-talk model (6) that focuses on shared decision-
making in clinical practice, and the use of health outcomes and
economic analyses (7). In particular, since the introduction of
the Orphan Drug Regulation in Europe in 2000 (8), healthcare
systems and reimbursement bodies have had to consider new
ways of assessing the value-add of rare disease treatments.
Methodologies have ranged from cost-effectiveness models (5, 9),
to budget impact models (10) and other tools such as multi-
criteria decision analysis (MCDA) (11).
While the European Medicines Agency (EMA) grants the
marketing authorization for treatments in Europe (12), the
reimbursement decisions are made a local country level (13, 14).
Despite the introduction of the Mechanism of Coordinated
Access to orphan medicinal products (MoCA) (15), and the
commitment by member states to collaborate on improving
access to treatments for rare diseases (16), access to orphan drugs
across Europe remains variable due to different reimbursement
decisions in each country (14, 17). In England, for example, less
than 50% of centrally authorized orphan drugs are funded by the
National Health Service, with one-third of these recommended
by the National Institute for Health and Care Excellence
(NICE) (14). The issue of access to orphan drugs might
further be complicated by the difference in pricing (18) and
pricing negotiations from one country to another, and the
Abbreviations: AHP, Analytical hierarchy process; ASMR, Amélioration du
service médical rendu; HAS, Haute autorité de santé; HTA, Health technology
assessment; ISPOR, International Society for Pharmacoeconomics Outcomes
Research; MAUT, Multi-attribute utility theory; MCDA, Multi-criteria decision
analysis; NICE, National Institute for Health and Care Excellence; R&D, Research
and development.
metrics by which payers adjudicate the added value of the
orphan drug (19). In light of these complex issues, and the
increase in expensive orphan drugs (20, 21) different models are
being proposed to increase the confidence in the evidence for
reimbursement from pre-launch all the way through to post-
launch activities. Furthermore, some alternative reimbursement
models include patient access schemes (22), reference pricing
in pricing negotiations, “cost plus” pricing imposed by the
health technology assessment body (23), discount pricing (24)
managed entry agreements or managed access agreements (25)
and rebate schemes (26), (27). Ultimately, payers are faced
with an increasing need to use robust measures with which to
assess if new orphan drugs demonstrate value for money, while
considering the real clinical benefits and risk of adverse events
for the patients, while not wasting medical resources (28).
Recently, MCDA has gained increasing attention in
reimbursement decisions for orphan drugs (29, 30) as an
alternative to cost-effectiveness. The practice of MCDA in
decision-making processes has been used extensively in many
industries such as the aviation industry (31) and energy and
environmental industries (32) for many years. This particular
interest in MCDA is due to the belief that the traditional
cost-effectiveness approach used to assess the value of orphan
drugs is not robust enough to capture all the multi-dimensional
factors that inform on the real benefits of the treatment under
review (33, 34). Some of the earliest use of MCDA in healthcare
include a study in 1989 to review options in pyelonephritis
(35) and for haemoglobinopathies (36). Subsequent use of
MCDA in healthcare has been intermittent. To support the
development of MCDA for orphan drugs and decision-making
by health technology assessment (HTA) bodies and payers, The
International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Taskforce in multi-criteria decision analysis
published recommendations on MCDA (37, 38). However, the
ISPOR Taskforce reports are not payer-centric and don’t provide
insights on how to address the criterion of cost of orphan drugs.
The principle of MCDA is that it provides a matrix or
framework whereby multiple factors that describe the disease
and treatment under review can be arranged and assessed.
The MCDA framework includes the different drug options, the
criteria which measure the outcomes of the drugs being assessed,
the scaling system by which criteria are measured (allocated a
score) and the weights ascribed to the different criteria (38–40).
The choice of criteria is open to interpretation depending on
the decision question, although there seems to be a common list
of criteria that are considered appropriate for assessing orphan
drugs using MCDA, as described in the literature (34, 41, 42).
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Preferences or weights, that describe the relative importance of
the criteria against which the different treatments are compared,
can then be ascribed to each criterion. Finally, a total “drug score”
can be aggregated and used comparatively against other drugs
in decision-making and resource allocation (37, 43). Thereby,
the MCDA framework provides the opportunity to compare
qualitative and quantitative outcomes (44). There are various
methods in which to applyMCDA, with themost commonly used
ones being the multi-attribute utility theory (MAUT), Analytic
Hierarchy Process (AHP), and Outranking (45).
MCDA is being used in some healthcare systems to support
the allocation of resources. In England, the Advisory Group
for National Specialized Services (AGNSS) was the first health
technology assessment body to adopt MCDA to assess orphan
drugs (46) using a framework based on efficacy, societal value
of the new treatment, the cost of the new treatment, and impact
of the new treatment on service delivery (47). AGNSS was
subsequently taken over by the Highly Specialized Technologies
(HST) group for NICE, who also use the MCDA approach
(48). In Spain, the Spanish Agency for Medicines and Health
Products developed a MCDA framework based on the EVIDEM
framework (49) and similarly in Catalonia (50). The region of
Lombardia in Italy has adopted a MCDA approach to regulate
the introduction of new health technologies. Their MCDA is
based on the EVIDEM framework. The introduction of this
formal MCDA model stemmed from the desire to balance
goals of continuous innovation with the needs of steady cost
containment, and to instill uniformity and transparency in a
process that may be highly complex. While subjectivity cannot be
completely removed, the framework seeks to minimize discretion
in decision making and to produce decisions perceived as
legitimate by all the stakeholders (51).
Interestingly, the very earliest reference to MCDA seems to be
in a letter that Benjamin Franklin (one of the Founding Fathers
of the USA) wrote to an acquaintance in 1772. Benjamin Franklin
explained that when faced with multiple factors that influence a
decision, it is worth assessing the problem by dividing a page into
two columns labeled Pros and Cons under which the decision-
maker can list all the necessary factors. He further described his
method by saying “When I have thus got them all together in one
view, I endeavor to estimate their respective weights; and where
I find two, one on each side, that seem equal, I strike them both
out. If I find a reason pro equal to two reasons con, I strike out
the three. If I judge some two reasons con, equal to some three
reasons pro, I strike out the five; and thus proceeding I find at
length where the balance lies; and if, after a day or two of further
consideration, nothing new that is of importance occurs on either
side, I come to a determination accordingly” (52).
Benjamin Franklin’s letter alludes to a key point in the
use of MCDA, and particularly in assessing orphan drugs—
namely the use of weights, or preferences of the different
criteria, thereby implying that not all criteria should carry the
same importance and that the MCDA model should reflect the
weighted preferences. In assessing orphan drugs using MCDA,
it could therefore be postulated that Disease severity might be
more important than Disease rarity, for example. The weighting
is used when aggregating all the criteria to establish the overall
“value” (score) of the drug, and the weighting score allocated
to a criterion is independent of individual score given to each
criterion. For example, the Treatment convenience of a drug
might be scored as “high” (meaning that the drug offers easy
administration with low associated costs), but the criterion is not
considered important by the adjudicating panel, and is therefore
given a low weight (preference) in aggregating all the criteria
scores for each drug.
While ample research has been performed in recent years on
the suitable criteria for inclusion in a MCDA model for orphan
drugs (42, 50, 53), less research seems to have been done on the
weights or preferences that should be applied to the different
criteria. The weighting scales used in research range from 5-point
scales (50, 54), to 10-point scales (55) and several studies mention
using a 100-point scale (34, 41, 56). A pilot study by Reddy
et al. included a group of eight participants (plus the facilitator)
to select the criteria that should be considered for a MCDA
framework for several public health preventative programmes.
They adopted an AHP approach to weight each criterion, thereby
obtaining a total score for each under discussion (57). Although
this pilot study focused on the choice of topics with which to
assess which criteria for public health programmes rather than
for rare disease treatments, it highlights the benefits and some of
the potential pitfalls of using AHP and MCDA.
The aim of this study was to ascertain the preferences for
different criteria from many participants, by comparing the
results gathered in a large respondent pool with those from a
focus group of experts. The target audience is anyone interested
in assessing if MCDA has a role to play in reimbursement
decisions for orphan drugs. The authors hope that the research
would help further increase the dialogue on the use of alternative
methods to assess the value of orphan drugs in addition to
cost-effectiveness. Intentionally, the authors did not include a
discussion on orphan drug prices, as the key aim was to better
understand the weight preferences for all other criteria that might
be included in a MCDA framework. In the follow-up study that
is planned using a far larger group of respondents from many
different countries, the orphan drug prices will be prioritized
for debate.
METHOD
Using key MCDA criteria for orphan drugs reported in the
literature (34, 41, 42, 58), we developed a web-based interactive
tool (59) to capture preferences for different criteria from a
general stakeholder sample attending medical, healthcare or
health economic conferences. The criteria were divided into 4
major categories: Disease Burden, Product Development, Clinical
Impact and Economic Impact. The tool was designed so that
respondents could allocate any weight to the criteria by means
of a sliding scale up to a total of 100% and allowing for the
inclusion of as many of the criteria as the respondent wanted.
i.e., not all criteria had to be allocated a weight. Respondents
were asked to use the tool based on what they deemed important
in reimbursement decisions. The tool invited respondents to
select their field of expertise (e.g., academia, industry) or
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affiliation (patient representative organization) and the country
in which they worked. Once the respondent had completed their
weighting, a comparative output showed by how much their
inputs deviated from the existing sample average, both as an
overall average as well as a diagrammatic representation for
each criterion.
We subsequently conducted an expert focus group to gather
additional insights from different perspectives on the weights
that could be allocated to different criteria when MCDA is used
to assess orphan drugs. To this end, we recruited a panel of
ten people, all based in Switzerland, comprised of two payers
(one each from the state and private insurance sectors), two
clinicians specialized in rare diseases (different diseases), two
clinical Pharmacists (both working in large teaching hospitals),
two health economists (one each from academia and private
health insurance), and two patient representatives from different
rare disease organizations. Panel recruitment invitations were
distributed by personal contact with each participant, with
explanations of the study outline, objectives and detailed
descriptive information about each criterion included in the tool
(summarized in Table 1).
We conducted the focus group session according to published
focus group methodology (60) in a face-to-face group session
held at the hospital in Lausanne, Switzerland. The session
was run in English and all participants were fluent English
speakers. We initiated the session by describing each criterion
and demonstrating how the interactive tool worked. The focus
group participants were then invited to each use the interactive
tool and to complete the weighting exercise from the perspective
of their employment role rather than from a societal perspective.
In contrast to the larger study, the focus group participants were
asked to provide reasoning for their choices. Following a group
TABLE 1 | Summarized descriptions of criteria provided to the expert focus group.
Treatment efficacy The degree of improvement of the standard outcome by which a drug’s efficacy is measured against the most
likely comparator in a specific disease.
Disease severity An attribute that reflects the severity of:
• Disease-related mortality
• How symptomatic the disease is
• Mental status (anxiety/depression)
• Physical implications &/disability
Unmet need A criterion that reflects:
• Number of treatment alternatives
• Benefit from the alternative treatment
Level of research undertaken A criterion that considers:
• Level of trials undertaken (e.g., phase 2 vs. phase 3)
• Trial duration
• Size of the trial:
• Number of study centers
• Number of patients included
Innovation Based on a description of the ASMR system used by the HAS in France
Dynamic efficiency (R&D spillover) Where the research and development costs for one indication leads to discovery of the drug’s value in a second
indication that does not require the same level of extensive R&D investment
Treatment safety A criterion that summarizes the:
• Serious adverse events in clinical trials (30%)
• Treatment discontinuation due to adverse events (30%)
• Treatment-related mortality (40%)
Treatment convenience • Route of administration
• Frequency of administration
• Time to administer treatment
• Duration of treatment (weeks, months, years)
Treatment follow-up measures • Test complexity
• Test frequency
Budget impact/Affordability The local healthcare economy’s perception of how much a new treatment will impact on the budget
Broader economic consequences Any additional economic benefits that a treatment offers. E.g. being able to work, reduced absenteeism from
school &/ work
Value for money (cost-effectiveness) The criterion captures an understanding of how resources are transformed into valued health system outputs
Smith, who, measuring value for money in healthcare, concepts and tools
Disease rarity Based on levels of disease prevalence with a guideline of:
• 0.01 to 5 per 100,000 population
• 5.1 to 66 per 100,000
• 67 to 100 per 100,000
• 101 to 200 per 100,000
• 201 to 300 per 100,000
• > 301 per 100,000
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discussion of each criterion, the participants had the opportunity
to change their weighting if they so desired.
RESULTS
General Stakeholder Sample Weight
Preference Data Collection
The interactive tool was completed by 120 respondents from a
wide range of professional backgrounds and multiple countries.
The country representation and professional affiliations of the
large pool respondents are listed in Tables 2, 3, respectively. The
largest representation of respondents were from the USA (13%),
the Netherlands (12%), Belgium, and Germany (both 10%). The
highest number of professional affiliations were Academia and
Industry (Pharmaceutical/Medical devices/Diagnostics) at 27%
and 23%, respectively.
Figure 1 shows the average weights of the criteria for all
respondents in the general stakeholder sample, which highlights
that Treatment efficacywas considered the criterion that deserved
the highest weight, followed closely by Disease severity and then
Unmet need. The respondents scored Dynamic efficiency (R&D
spillover) as the criterion with the least importance.





























United States of America 13%
Focus Group Weight Preference Data
Collection and Discussion
Table 4 lists the weight preferences for each of the participants
of the expert focus group session after the group discussion
and having had the opportunity to change their choices if they
so wished.
The numbers in red cells are those that were decreased and
those in green cells were increased. Both the medical doctors and
the patient representatives were pleased with their initial choices,
while all the other respondents made some changes.
The discussion provided some useful insights herewith
summarized according to each criterion. The general consensus
was that Disease severity can have a significant negative impact
on the health-related quality of life of patients, especially for
those with progressive rare, genetic disease. Following the group
discussion, a Pharmacist and a Health Economist each decreased
their weight allocation from 20 and 18%, respectively, to 10%,
while the Payers increased their respective weights from 0
to 5% and 10%. By contrast, Disease rarity was considered
to not be a significant criterion, and further downplayed
following discussion, as seen in the changes made by 2 members
(Pharmacist & Health Economist). It was felt that in light of the
Orphan Drug Regulation in Europe, the rarity of disease was
already accounted for in the incentives made available to drug
manufacturers. As with the general stakeholder sample, the focus
group felt that Treatment efficacy was the criterion that deserved
the most weight, with Treatment safety in very close second.
Across the group, 70% of the members agreed that Unmet
need, which related to the availability of suitable treatment(s), was
an important criterion scoring it a weight of an average of 10.57%
whereas 30% of the group believed that the criterion should
somehow be linked to the drug’s efficacy and safety, implying
that Unmet need alone was not important enough to warrant a
high weight.
The initial weight bestowed upon Level of research undertaken
ranged from 5% (Health Economist) to 21% (Pharmacist). In
three cases, the weight was increased following the discussion
(pharmacist, health economist & public sector payer) and the
private-sector payer (private sector) reduced the weight slightly
(14–13%). Innovation is a criterion that was not considered at all
important and on average was given a weight of only 2%.
Dynamic efficiency (R&D spillover), where the development
of a drug for one indication leads to the drug being







Managed care/pharmacy benefit management 4%
Patient 8%
Biotech 3%
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FIGURE 1 | The average weight scores for the general stakeholder sample.
effective in a second indication or the advent of added
benefits from the research and development of the drug,
was viewed as an unimportant criterion even though a
subsequent indication could influence the price, sales volume and
reimbursement negotiations.
Treatment convenience, which relates to the route of
administration and frequency of administration, was awarded
a relatively low weight. Similarly, Treatment follow-up measures
was considered a relatively unimportant criterion, although one
of the clinicians pointed out the potential cost implications of a
treatment that would require very regular costly monitoring.
The economic criteria of Budget impact/Affordability,
Broader economic consequences and Value for money (cost-
effectiveness) were awarded a wide range of weights with Budget
impact/Affordability being perceived as the most important of
the economic criteria. These criteria experienced only minor
changes in weights after the discussion. Overall, the average
weights were 7, 6, and 5% for Budget impact/Affordability,
Broader economic consequences and Value for money (cost-
effectiveness), respectively. The average results are shown
comparatively for both sets of respondents in Table 5, which
highlights significant differences in the perception of the 2
groups (the large group vs the expert group), most notably for
Treatment efficacy and Treatment safety that are both favoured
by the expert focus group. The variations between the groups
with respect to the economic criteria are not significant.
DISCUSSION
This study identified the perspective of a large group of people
(120 respondents) and an expert focus group via an interactive
tool, on the suggested weights of commonly cited criteria
suggested for use in assessing the value of orphan drugs by means
of MCDA. Although both groups applied the highest weight to
Treatment efficacy, the results show that the expert group favored
the Clinical Impact criteria (Treatment efficacy, Treatment safety,
Treatment convenience, Treatment follow-up measures), and the
large group, who did not have the benefit of any discussions,
weighted the Disease Burden criteria (Disease severity, Unmet
need, Disease rarity) the most.
With each group of respondents basing their choices from
a reimbursement perspective as indicated in the instructions,
the results suggest that having the opportunity to discuss the
criteria and their impact within a small, expert group gives
additional insights of the importance, and therefore the weights,
of some key criteria. As a result of the group discussion, three
members increased the weight for Level of research undertaken
on the basis that the more extensive the clinical research, the
less the uncertainty of outcomes in the real clinical setting,
and therefore the more the criterion should be weighted with
a scale that describes different levels of research. These changes
made to Level of research undertaken by the expert group, and
difference between the average weights allocated to the criterion
by both groups suggests that the interactive forum assisted weight
allocation by respondents.
One of the main advantages of the group discussion is that
it provides a confidential platform for participants to openly
comment, explain, disagree, and share their views, perspectives
and knowledge (61). Although the focus group session enabled
themembers to respond in their ownwords and to share opinions
in a non-judgmental way, it was also a structured session aimed
at allowing us to obtain information pertinent to the study. In
the pilot performed by Sussex et al., they included stakeholders
who worked in a pharmaceutical company (GlaxoSmithKline),
EU clinical and health economics experts, and representatives of
rare diseases patient groups in the EU. In our study, we excluded
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TABLE 4 | Weight allocations after the focus group discussion for the expert focus group.
Criterion CL 1 Cl 2 PH 1 PH 2 HE 1 HE 2 PY 1 PY 2 PR 1 PR 2
Disease Disease severity 11% 15% 11% 10% 10% 10% 5% 10% 10% 10%
Disease rarity 0 0 0% 0 0 0% 0 0 0 0
Unmet need 10% 11% 13% 5% 10% 10% 0 0 10% 10%
Product development Level of research undertaken 10% 11% 15% 21% 8% 10% 10% 13% 15% 15%
Innovation 0 0 0 4% 3% 5% 0 0% 0 5%
Dynamic efficiency (R&D spill over) 0 0 0 0 2% 5% 0 0% 0 0
Clinical impact Treatment safety 26% 17% 22% 18% 18% 20% 18% 15% 20% 23%
Treatment efficacy 26% 25% 22% 20% 18% 20% 18% 19% 25% 20%
Treatment convenience 8% 3% 0 0 8% 0 9% 0 5% 5%
Treatment follow up measures 9% 6% 0 0 5% 0 3% 8% 5% 5%
Economic impact Budget impact/affordability 0 0 17% 0 9% 17% 11.0% 13% 0 0
Broader economic consequences 0 12% 0 0 9% 3% 11.0% 11% 10% 7%
Value for money (cost-effectiveness) 0 0 0 22% 0 0 15% 11% 0 0




PY 1: Payer (state).
PY 2: Payer (private insurance).
PR: Patient representative.
TABLE 5 | Comparative weights between the two study groups.
Criteria groups Criteria Large group Expert Focus
group
(n = 120) (%) (n = 10) (%)
Disease burden Disease severity 13.05 10
Unmet need 12.89 8
Disease rarity 4.92 0







Clinical impact Treatment efficacy 15.79 21
Treatment safety 12.03 20













representation from the pharmaceutical industry sector to ensure
that the members felt free to share their opinions. We included
payers from the state-funded and private insurance sectors to
identify potential differences in perspectives.
One of the points that raised debate among the participants
was what they referred to as “double counting,” especially
for Unmet need, which initially several members felt was
already captured in Disease severity. However, as one of the
clinicians described, a patient could present with a very severe
disease but for which there are several treatments, such as
pulmonary arterial hypertension, in which case the unmet need
is not substantial compared to an equally severe disease for
which there is no treatment. The participants suggested that
another area at risk of “double counting” are the economic
criteria, and that clear differentiation needs to be made between
Budget impact/Affordability, Broader economic consequences,
and Value for money/cost-effectiveness. In particular, the sub-
categories for Broader economic consequences would need to be
clearly defined.
In exploring the weights for Treatment efficacy and Treatment
safety, two members of the focus group commented that at the
point that they consider drugs from a reimbursement perspective,
the drug would have been approved by the European Medicines
Agency or an equivalent organization (Federal Office of Public
Health, Switzerland), and therefore it can be assumed that that
both the efficacy and safety of the new product meet at least
the expected minimum standards, and therefore these 2 criteria
should not necessarily be weighted as much as the trend seemed
to be.
One of the limitations of this study relates to the nature
of the 2 groups. Under ideal conditions, it would be advisable
to have multi-country representation in the expert focus group
rather than only representation from Switzerland, thereby
giving breadth to the discussion and outcomes. Nonetheless,
this provided a valuable opportunity to test the concept and
approach, which can now be refined and rolled out to a
larger, multi-national, multi-stakeholder expert focus group.
Similarly, the representation in the large group was not
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spread evenly by country nor profession. Since the tool is
web-based, we plan to further test it by sharing it with a
far wider audience, although we believe that group sessions
and the discussions they elicit are far more beneficial than
individual responses.
A further limitation was that the focus group included only
one payer from the public sector, the sector. However, in a
country where most medicines used in the community are
funded through private insurance or out-of-pocket for patients,
it was deemed appropriate to include a payer from the private
insurance sector.
A clear omission in this study is the lack of attention given
to the pricing of orphan drugs. The ever-increasing cost of
orphan drugs is clearly a major cause for concern for payers and
healthcare systems. The rationale for this omission was so that the
focus would be only on reviewing the weighting preferences for
all other criteria, and to avoid the discussion leading to criticism
of orphan drug pricing, an issue that is frequently addressed in
the media (62–64).
While the Level of research undertaken seemed to be of
significant importance to the expert focus group with an average
weight of 13%, the general stakeholder sample scored it an
average of 7.28%. Other Product Development criteria (Dynamic
efficiency (R&D spillover), Innovation) were considered less
important by both groups. Dynamic efficiency (R&D spillover)
was viewed as a criterion that depended on changes in the future
that could only be judged retrospectively, most likely after a
substantial lapse of time. The expert focus group discussion
led to a heated debate on Innovation. The participants voiced
concern for how to judge a drug’s level of innovation, with
some members referring to the emergence of gene therapy as
potentially clouding the understanding of the criterion. The
scoring system adopted in France by the Haute autorité de
santé (HAS), l’amélioration du service médical rendu (ASMR;
the improvement in actual benefit) (65) was considered a “good
starting point” although the difference between the levels was
deemed unclear. Furthermore, currently there is much debate
about real innovation in orphan drugs because if a new treatment
comes to market for a disease for which there is no treatment,
then purely by comparison, the new treatment might be deemed
“innovative,” whilst not necessarily providing as innovative an
outcome as necessary to justify some of the high prices demanded
(66). It has also been argued that the use of “salami slicing” and
re-purposing of drugs merely serve to generate treatments for
more indications, but without generating added innovation (67).
Payers are increasingly scrutinizing the cost-benefit ratio of new
orphan drugs (68).
It is of interest that Treatment convenience was perceived
as an unimportant criterion given that if a drug has to be
administered frequently in a clinical setting, it is likely to
incur far more costs than a treatment that is self-administered
by the patient (oral, self-inject). Furthermore, one could
argue that a drug that is difficult to administer or that
has to be taken multiple times daily is likely to result in
poor treatment adherence (69, 70), which has a ripple of
effect of suboptimal treatment outcomes, an increased risk of
hospitalization (70) and wasted resources, all with negative
economic outcomes.
CONCLUSION
MCDA frameworks are complex models with increasing
complexity as more criteria are added to the decision-making
process and additional evidence generation is required (71).
Some people might consider that replacing a cost-effectiveness
analysis with MCDA results in added uncertainty of what the
results really imply in the context of reimbursement decisions.
On the one hand, HTA bodies have gained many years of
experience in interpreting cost-effectiveness model outcomes.
However, there is concern that cost-effectiveness does not offer a
realistic method to consider an orphan drug’s value-add because
it does not consider the multi-dimensional factors relating to
the rare disease and its treatment. Conversely, MCDA offers
added insights in value assessments of orphan drugs, but at this
point, there is limited experience using MCDA. This study sheds
light on the important aspect of the preferences of the different
criteria. All respondents agreed on the relative importance of
Treatment efficacy and Treatment safety, which are captured in
conventional cost-effectiveness studies, but they also expressed
the view thatDisease severity, Level of research undertaken (which
could contribute to addressing uncertainty) and Unmet need
should definitely be included in MCDA frameworks for assessing
orphan drugs.
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